Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02460094 | Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy | PHASE1 | COMPLETED | 48 | — | — | Oct 2, 2015 | Oct 19, 2016 | Sep 4, 2018 | 13 | United States |
| Arm | Type | Description |
|---|---|---|
| Panel 1: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Panel 2: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Panel 3: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Panel 4: BIIB092/ Placebo | EXPERIMENTAL | BIIB092 or matching placebo administered by intravenous (IV) injection, up to a maximum of 3 doses once every four weeks. |
| Name | Type | Description |
|---|---|---|
| BIIB092 | DRUG | See Arm Descriptions for dosing information. |
| Placebo | DRUG | See Arm Descriptions for dosing information. (0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available) |
Inclusion Criteria 1. Probable or possible PSP defined as: * at least a 12-month history of postural instability or falls during the first 3 years that symptoms are present * a decreased downward saccade velocity at screening defined as observable eye movement deviation from the "main sequen...